MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1101/2023.11.22.23298907

Медицинская библиотека · medRxiv : the preprint server for health sciences · 2023

Baseline malaria infection status and RTS,S/AS01E malaria vaccine efficacy.

Juraska Michal, Early Angela M, Li Li, Schaffner Stephen F, Lievens Marc, Khorgade Akanksha, Simpkins Brian, Hejazi Nima S, Benkeser David A, Wang Qi, Mercer Laina D, Adjei Samuel, Agbenyega Tsiri, Anderson Scott, Ansong Daniel, Bii Dennis K, Buabeng Patrick B Y, English Sean, Fitzgerald Nicholas, Grimsby Jonna, Kariuki Simon K, Otieno Kephas, Roman François, Samuels Aaron M, Westercamp Nelli, Ockenhouse Christian F, Ofori-Anyinam Opokua, Lee Cynthia K, MacInnis Bronwyn L, Wirth Dyann F, Gilbert Peter B, Neafsey Daniel E

ПрепринтСтатьяПеревод в очереди

Аннотация

BACKGROUND

The only licensed malaria vaccine, RTS,S/AS01 E , confers moderate protection against symptomatic disease. Because many malaria infections are asymptomatic, we conducted a large-scale longitudinal parasite genotyping study of samples from a clinical trial exploring how vaccine dosing regimen affects vaccine efficacy (VE).

METHODS

1,500 children aged 5-17 months were randomized to receive four different RTS,S/AS01 E regimens or a rabies control vaccine in a phase 2b clinical trial in Ghana and Kenya. We evaluated the time to the first new genotypically detected infection and the total number of new infections during two follow-up periods in over 36K participant specimens. We performed a post hoc analysis of VE based on malaria infection status at first vaccination and force of infection.

RESULTS

We observed significant and comparable VE (25-43%, 95% CI union 9-53%) against first new infection for all four RTS,S/AS01 E regimens across both follow-up periods (12 and 20 months). Each RTS,S/AS01 E regimen significantly reduced the number of new infections in the 20-month follow-up period (control mean 4.1 vs. RTS,S/AS01 E mean 2.6-3.0). VE against first new infection was significantly higher in participants who were malaria-infected (68%; 95% CI, 50 to 80%) versus uninfected (37%; 95% CI, 23 to 48%) at the first vaccination (P=0.0053) and in participants experiencing greater force of infection between dose 1 and 3 (P=0.059).

CONCLUSIONS

All tested dosing regimens blocked some infections to a similar degree. Improved VE in participants infected during vaccination could suggest new strategies for highly efficacious malaria vaccine development and implementation. ( ClinicalTrials.gov number, NCT03276962 ).

Для цитирования: Juraska Michal, Early Angela M, Li Li, Schaffner Stephen F, Lievens Marc, Khorgade Akanksha, Simpkins Brian, Hejazi Nima S, Benkeser David A, Wang Qi, Mercer Laina D, Adjei Samuel, Agbenyega Tsiri, Anderson Scott, Ansong Daniel, Bii Dennis K, Buabeng Patrick B Y, English Sean, Fitzgerald Nicholas, Grimsby Jonna, Kariuki Simon K, Otieno Kephas, Roman François, Samuels Aaron M, Westercamp Nelli, Ockenhouse Christian F, Ofori-Anyinam Opokua, Lee Cynthia K, MacInnis Bronwyn L, Wirth Dyann F, Gilbert Peter B, Neafsey Daniel E. Baseline malaria infection status and RTS,S/AS01E malaria vaccine efficacy.. medRxiv : the preprint server for health sciences. 2023. DOI: 10.1101/2023.11.22.23298907.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.